- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Diffuse large B-cell lymphoma (DLBCL)
- Meeting Date: March 2025
- Public Summary Document (PSD) March 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2025 PBAC Meeting - (Word)
Polatuzumab Vedotin – March 2025
Polatuzumab Vedotin; Powder for I.V. infusion 30 mg, Powder for I.V. infusion 140 mg; Polivy®
Last updated
12 March 2025